Wide-complex tachycardia: Difference between revisions

(Text replacement - "prn" to "PRN")
Line 18: Line 18:
==Management==
==Management==
''Pulseless: see [[Adult pulseless arrest]]''
''Pulseless: see [[Adult pulseless arrest]]''
*Unstable:
===Unstable===
**Regular: Synchronized cardioversion 100-200J
*Regular: Synchronized cardioversion 100-200J
**Irregular: Unsynchronized cardioversion ([[defibrillation]]) 200J
*Irregular: Unsynchronized cardioversion ([[defibrillation]]) 200J
*Stable
===Stable===
**Regular (treat as presumed V-tach)
*[[Procainamide]] 100 mg q5min at max rate of 25-50 mg/min<ref>Procainamide. GlobalRPH. http://www.globalrph.com/procainamide_dilution.htm.</ref>
***[[Procainamide]] 100 mg q5min at max rate of 25-50 mg/min<ref>Procainamide. GlobalRPH. http://www.globalrph.com/procainamide_dilution.htm.</ref>
**Until termination of arrhythmia, then start 2-6 mg/min (or 1-2 mg/min for renal/cardiac failure)
****Until termination of arrhythmia, then start 2-6 mg/min (or 1-2 mg/min for renal/cardiac failure)
**'''OR''' max 17 mg/kg total dose given (12 mg/kg if renal failure)
****'''OR''' max 17 mg/kg total dose given (12 mg/kg if renal failure)
**'''OR''' if QRS widens > 50%
****'''OR''' if QRS widens > 50%
*[[Amiodarone]], agent of choice in setting of AMI or LV dysfunction
***[[Amiodarone]], agent of choice in setting of AMI or LV dysfunction
**150 mg over 10min (15 mg/min), followed by 1 mg/min drip over 6hrs (360 mg total)<ref>Amiodarone. GlobalRPH. http://www.globalrph.com/amiodarone_dilution.htm.</ref>
****150 mg over 10min (15 mg/min), followed by 1 mg/min drip over 6hrs (360 mg total)<ref>Amiodarone. GlobalRPH. http://www.globalrph.com/amiodarone_dilution.htm.</ref>
**Then 0.5 mg/min drip over next 18 hrs (540 mg total)
****Then 0.5 mg/min drip over next 18 hrs (540 mg total)
**Oral dosage after IV infusion is 400 -800 mg PO daily
****Oral dosage after IV infusion depends on IV infusion length:
*[[Lidocaine]] 1-1.5mg/kg IV q5min, repeat PRN until up to 300mg/hr
*****< 1 wk IV infusion: 800-1600 mg PO QD
===Refractory===
*****1-3 wks: 600-800 mg PO QD
*≥3 episodes within 24 hours considered [[electrical storm]] and may require alternate treatment (i.e. beta blockade, sedation, ablation)
*****> 3 wks: 400 mg PO QD
*In very wide complex (>0.2 msec) and <120 bpm in a patient with significant history, consider giving [[Calcium chloride|calcium chloride]] to treat [[Hyperkalemia|hyperkalemia]] and  
***[[Lidocaine]] 1-1.5mg/kg IV q5min, repeat PRN until up to 300mg/hr
===Other considerations===
**Irregular (treat as presumed preexcited [[A-fib]])
*Consider [[Bicarbonate]] for Na channelopathy such as [[Benadryl]], [[TCA toxicity]] or [[Cocaine]] overdose
***[[Procainamide]] as above
***[[Amiodarone]] as above
***[[Sotalol]] (100mg IV over 5 minutes)
***[[Magnesium]] 1-2gm IV over 60-90s, then infuse 1-2gm/hr (for [[Torsades De Pointes]])
*Refractory
**≥3 episodes within 24 hours considered [[electrical storm]] and may require alternate treatment (i.e. beta blockade, sedation, ablation)
*In very wide complex (>0.2 msec) and <120 bpm in a patient with significant history, consider giving [[Calcium chloride|calcium chloride]] to treat [[Hyperkalemia|hyperkalemia]] and [[Bicarbonate]] for Na channelopathy
**Usually Vtach is >120 bpm
**Usually Vtach is >120 bpm
**[[Hyperkalemia]], [[Acidosis]], [[TCA toxicity]] poison Na channels
**Also consider [[Hyperkalemia]] or [[Acidosis]] as reversible causes
**[[Lidocaine]], [[Procainamide]], [[Amiodarone]] all block Na channels and may result in asystole in these patients
**[[Lidocaine]], [[Procainamide]], [[Amiodarone]] all block Na channels and may result in asystole in patients with intrinsic or extrinsic Na-channel blockade


==Disposition==
==Disposition==

Revision as of 18:40, 13 July 2017

Background

  • Consider Hyperkalemia, Dig Toxicity, severe metabolic acidosis
  • Sustained ventricular tachycardia is VT > 30 seconds
  • 3 beats is considered VT; less than 30 seconds is non-sustained VT

Epidemiology[1][2][3]

  • WCT is due to ventricular tachycardia in 80% of cases
  • For patients with underlying cardiac disease, this number increases to > 90%

Differential Diagnosis

Wide-complex tachycardia

Assume any wide-complex tachycardia is ventricular tachycardia until proven otherwise (it is safer to incorrectly assume a ventricular dysrhythmia than supraventricular tachycardia with abberancy)

^Fixed or rate-related

Evaluation

Ventricular tachycardia
  • Assume ventricular tachycardia until proven otherwise
  • See V Tach vs. SVT

Management

Pulseless: see Adult pulseless arrest

Unstable

  • Regular: Synchronized cardioversion 100-200J
  • Irregular: Unsynchronized cardioversion (defibrillation) 200J

Stable

  • Procainamide 100 mg q5min at max rate of 25-50 mg/min[4]
    • Until termination of arrhythmia, then start 2-6 mg/min (or 1-2 mg/min for renal/cardiac failure)
    • OR max 17 mg/kg total dose given (12 mg/kg if renal failure)
    • OR if QRS widens > 50%
  • Amiodarone, agent of choice in setting of AMI or LV dysfunction
    • 150 mg over 10min (15 mg/min), followed by 1 mg/min drip over 6hrs (360 mg total)[5]
    • Then 0.5 mg/min drip over next 18 hrs (540 mg total)
    • Oral dosage after IV infusion is 400 -800 mg PO daily
  • Lidocaine 1-1.5mg/kg IV q5min, repeat PRN until up to 300mg/hr

Refractory

  • ≥3 episodes within 24 hours considered electrical storm and may require alternate treatment (i.e. beta blockade, sedation, ablation)
  • In very wide complex (>0.2 msec) and <120 bpm in a patient with significant history, consider giving calcium chloride to treat hyperkalemia and

Other considerations

Disposition

  • Admit all patients (even if converted to NSR with adenosine)

See Also

References

  1. Gupta AK, Thakur RK. Wide QRS complex tachycardias. Med Clin North Am. 2001;85(2):245–66– ix–x.
  2. Akhtar M, Shenasa M, Jazayeri M, Caceres J, Tchou PJ. Wide QRS complex tachycardia. Reappraisal of a common clinical problem. Ann Intern Med. 1988;109(11):905–912.
  3. Stewart RB, Bardy GH, Greene HL. Wide complex tachycardia: misdiagnosis and outcome after emergent therapy. Ann Intern Med. 1986;104(6):766–771.
  4. Procainamide. GlobalRPH. http://www.globalrph.com/procainamide_dilution.htm.
  5. Amiodarone. GlobalRPH. http://www.globalrph.com/amiodarone_dilution.htm.